HRP20130966T1 - Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-3-ona - Google Patents

Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-3-ona Download PDF

Info

Publication number
HRP20130966T1
HRP20130966T1 HRP20130966TT HRP20130966T HRP20130966T1 HR P20130966 T1 HRP20130966 T1 HR P20130966T1 HR P20130966T T HRP20130966T T HR P20130966TT HR P20130966 T HRP20130966 T HR P20130966T HR P20130966 T1 HRP20130966 T1 HR P20130966T1
Authority
HR
Croatia
Prior art keywords
formula
compound
process according
image
iii
Prior art date
Application number
HRP20130966TT
Other languages
English (en)
Inventor
George W. Muller
Manohar T. Saindane
Chuansheng Ge
Roger Chen
Original Assignee
Celgene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37305020&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130966(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corporation filed Critical Celgene Corporation
Publication of HRP20130966T1 publication Critical patent/HRP20130966T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Claims (17)

1. Postupak dobivanja spoja Formule (I): [image] , ili njegove farmaceutski prihvatljive soli, solvata, polimorfa ili stereoizomera, naznačen time što se sastoji u koraku cikliziranja spoja Formule (II) ili (IIA): [image] , ili njegove soli s ciklizirajućim sredstvom Formule (V): [image] , gdje je R1 H, F, benzil, (C1-C8)alkil, (C2-C8)alkenil ili (C2-C8)alkinil; a svaki od X i Y je neovisno nesupstituirani ili supstituirani imidazolil, benzimidazolil ili benzotriazolil.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je spoj Formule (I) solvat koji je hidrat.
3. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je ciklizirajuće sredstvo spoj karbonildiimidazola, po mogućnosti 1,1′-karbonildiimidazol, poželjnije gdje je omjer između spoja Formule (II) ili (IIA) i 1,1′-karbonildiimidazola od otprilike 1:1 do otprilike 1:1,2.
4. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je ciklizirajuće sredstvo 1,1′-karbonildiimidazol, te što se korak cikliziranja provodi u otapalu, po mogućnosti u acetonitrilu ili N-metilpirolidinonu.
5. Postupak u skladu s patentnim zahtjevom 4, naznačen time što je otapalo acetonitril, a temperatura reakcije je od otprilike 80 °C do otprilike 87 °C, a po mogućnosti je trajanje reakcije od otprilike 1 sat do otprilike 5 sati.
6. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se spoj Formule (II) ili (IIA) dobiva reduciranjem spoja Formule (III) odnosno (IIIA): [image] reducensom, gdje je R1 H, F, benzil, (C1-C8)alkil, (C2-C8)alkenil ili (C2-C8)alkinil.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time što je reducens vodik uz 10% Pd/C; gdje je vodik izborno pod tlakom od otprilike 2,76 bar (276 kPa) do otprilike 3,45 bar (345 kPa), ili se reakciju provodi u otapalu, po mogućnosti u metanolu.
8. Postupak u skladu s patentnim zahtjevom 6, naznačen time što se spoj Formule (III) ili (IIIA) dobiva reakcijom 3-nitroftalanhidrida sa spojem Formule (IV) odnosno (IVA): [image] , gdje je R1 H, F, benzil, (C1-C8)alkil, (C2-C8)alkenil ili (C2-C8)alkinil.
9. Postupak u skladu s patentnim zahtjevom 8, naznačen time što se reakciju provodi u otapalu, gdje je po mogućnosti otapalo dimetilformamid, ili je temperatura reakcije od otprilike 80 °C do otprilike 87 °C.
10. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je spoj Formule (I) slobodni amin; gdje postupak izborno dodatno uključuje korak reakcije slobodnog amina s kiselinom, po mogućnosti klorovodičnom kiselinom, u molarnom omjeru od otprilike 1:1, kako bi se dobilo sol s kiselinom.
11. Postupak u skladu s patentnim zahtjevom 6, naznačen time što se spoj Formule (III) dobiva u koracima: (a) reakcije 3-nitro-N-etoksikarbonilftalimida s esterom glutamina Formule (VIII): [image] ili njegovom solju s kiselinom, u prisutnosti prvog katalizatora, kako bi se dobilo spoj Formule (IX) ili njegovu sol, solvat, polimorf ili stereoizomer: [image] ; i (b) reakcije spoja Formule (IX) ili njegove solu, solvata, polimorfa ili stereoizomera s klorovodikom, gdje je R1 H, F, benzil, (C1-C8)alkil, (C2-C8)alkenil ili (C2-C8)alkinil; a R8 je alkil ili aralkil.
12. Postupak u skladu s patentnim zahtjevom 11, naznačen time što dodatno uključuje korak dobivanja 3-nitro-N-etoksikarbonilftalimida reakcijom 3-nitroftalimida s etil-klorformijatom, u prisutnosti drugog katalizatora, gdje je po mogućnosti i prvi katalizator i drugi katalizator trietilamin.
13. Postupak u skladu s patentnim zahtjevom 12, naznačen time što je R1 H; a R8 je t-butil ili benzil; ili gdje je spoj Formule (VIII) hidroklorid t-butilnog estera l-glutamina, a spoj Formule (III) je (S)-enantiomer; ili gdje je spoj Formule (VIII) hidroklorid t-butilnog estera d-glutamina, a spoj Formule (III) je (R)-enantiomer; ili gdje je spoj Formule (VIII) racemična smjesa hidroklorida t-butilnog estera glutamina, a spoj Formule (III) je racemična smjesa.
14. Postupak u skladu s patentnim zahtjevom 1, 6 ili 8, naznačen time što je R1 H.
15. Postupak u skladu s patentnim zahtjevom 1, naznačen time što je spoj Formule (I) racemična smjesa, (+)-enantiomer ili (–)-enantiomer.
16. Postupak u skladu s patentnim zahtjevom 14, naznačen time što dodatno uključuje korak prekristaliziranja spoja Formule (I) iz smjese otapala koja se sastoji od dimetil-sulfoksida i vode.
17. Postupak u skladu s patentnim zahtjevom 16, naznačen time što je omjer između dimetil-sulfoksida i vode od 1:10 do 10:1, volumno, ili od 1:4 do 1:8, volumno.
HRP20130966TT 2005-06-30 2013-10-11 Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-3-ona HRP20130966T1 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69622405P 2005-06-30 2005-06-30

Publications (1)

Publication Number Publication Date
HRP20130966T1 true HRP20130966T1 (hr) 2013-11-22

Family

ID=37305020

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20130102TT HRP20130102T1 (hr) 2005-06-30 2013-02-06 Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
HRP20130966TT HRP20130966T1 (hr) 2005-06-30 2013-10-11 Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-3-ona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20130102TT HRP20130102T1 (hr) 2005-06-30 2013-02-06 Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona

Country Status (25)

Country Link
US (5) US7994327B2 (hr)
EP (2) EP1907373B1 (hr)
JP (2) JP5366544B2 (hr)
KR (2) KR101342241B1 (hr)
CN (2) CN102643267B (hr)
AU (1) AU2006265019B2 (hr)
BR (1) BRPI0612803A2 (hr)
CA (2) CA2612612C (hr)
CR (1) CR9697A (hr)
DK (2) DK1907373T3 (hr)
EC (1) ECSP088154A (hr)
ES (2) ES2402204T3 (hr)
HK (2) HK1121447A1 (hr)
HR (2) HRP20130102T1 (hr)
IL (2) IL188330A (hr)
ME (1) ME01513B (hr)
MX (1) MX2007016290A (hr)
NZ (1) NZ565309A (hr)
PE (2) PE20100151A1 (hr)
PL (2) PL2380887T3 (hr)
PT (2) PT1907373E (hr)
RS (2) RS53030B (hr)
SI (2) SI1907373T1 (hr)
WO (1) WO2007005972A1 (hr)
ZA (1) ZA200800828B (hr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ554068A (en) * 2004-09-03 2009-07-31 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
ME01513B (me) 2005-06-30 2014-04-20 Celgene Corp Postupak dobijanja spojeva 4-amin0-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
ZA200901852B (en) * 2006-09-15 2010-06-30 Celgene Corp N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
US8288414B2 (en) 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
CN101531653B (zh) * 2008-03-13 2014-07-09 峡江和美药业有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
US20110060010A1 (en) * 2008-03-13 2011-03-10 Tianjin Hemay Bio-Tech Co., Ltd Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
CN101580501B (zh) * 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
CN102060746B (zh) * 2009-06-01 2013-02-13 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
CN101817813B (zh) * 2010-01-15 2013-04-10 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物
DK2536706T3 (en) 2010-02-11 2017-08-14 Celgene Corp ARYLMETHOXYISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPREHENSIVE AND PROCEDURES FOR USING SAME
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
WO2013126326A1 (en) * 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
EP2877462B1 (en) * 2012-07-27 2019-09-04 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
CN104718202B (zh) * 2012-08-09 2018-11-20 细胞基因公司 用于制备(s)-3-(4-((4-(吗啉基甲基)苄基)氧基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮及其可药用形式的方法
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
WO2014170909A2 (en) * 2013-04-01 2014-10-23 Hetero Research Foundation Process for pomalidomide
AU2014248263A1 (en) 2013-04-02 2015-10-15 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
CN103232380A (zh) * 2013-05-08 2013-08-07 中国药科大学 一种泊马度胺关键中间体的制备方法
CN103275062B (zh) * 2013-05-17 2016-04-13 宁波百思佳医药科技有限公司 一种Pomalidomide的纯化方法
CN103288797B (zh) * 2013-05-17 2016-03-02 宁波百思佳医药科技有限公司 一种用亚砜类溶剂纯化Pomalidomide的方法
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
CN104557858B (zh) * 2013-10-29 2018-06-01 上海医药工业研究院 一种泊利度胺的制备方法
US20160362391A1 (en) * 2013-11-25 2016-12-15 Mylan Laboratories Ltd. Improved Process for the Preparation of Pomalidomide and its Purification
CN103724323B (zh) * 2014-01-20 2016-08-17 上海医药工业研究院 泊马度胺的制备方法
CN104016967A (zh) * 2014-04-04 2014-09-03 南京工业大学 一种泊利度胺的合成方法
CN105440013B (zh) * 2014-08-29 2018-10-09 杭州和泽医药科技有限公司 一种泊马度胺的制备方法
CN107406231B (zh) 2015-03-05 2019-11-15 奥的斯电梯公司 电梯轿厢
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
ITUB20169994A1 (it) 2016-01-14 2017-07-14 Phf Sa Nuove forme cristalline di farmaci immunomodulatori
HU231259B1 (hu) 2016-02-04 2022-06-28 Egyt Gyogyszervegyeszeti Gyar Eljárás pomalidomide elõállítására
CN106432045B (zh) * 2016-06-29 2018-12-18 深圳海王医药科技研究院有限公司 一种泊马度胺杂质的合成方法
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
WO2018154516A1 (en) * 2017-02-23 2018-08-30 Sun Pharmaceutical Industries Limited Process for the preparation of pomalidomide
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
US11439631B2 (en) * 2017-09-07 2022-09-13 “ChemImmune Therapeutics” Limited Liability Company Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
SI3784663T1 (sl) 2018-04-23 2023-11-30 Celgene Corporation Spojine substituiranega 4-aminoizoindolin-1,3-diona in njihova uporaba za zdravljenje limfoma
CN110343063A (zh) * 2019-08-09 2019-10-18 新乡双鹭药业有限公司 一种泊马度胺合成中杂质的制备方法
CN114605381A (zh) * 2020-12-03 2022-06-10 南京海辰药业股份有限公司 一种泊马度胺的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB858086A (en) * 1958-09-16 1961-01-04 American Cyanamid Co Method for synthesis of amides of imidazoles or benzimidazoles
US3979416A (en) * 1973-06-15 1976-09-07 Alelio Gaetano F D Preparation of aminophthalic anhydrides
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5637517A (en) * 1995-05-26 1997-06-10 Daewoo Electronics Co., Ltd. Method for forming array of thin film actuated mirrors
DE19601303A1 (de) * 1996-01-16 1997-07-17 Boehringer Ingelheim Kg Neuartige Benzoylguanidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
UA60308C2 (uk) 1996-07-24 2003-10-15 Селджін Корпорейшн ЗАМІЩЕНІ 2-(2,6-ДІОКСОПІПЕРИДИН-3-ІЛ)ФТАЛІМІДИ ТА 1-ОКСОІЗОІНДОЛІНИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЗНИЖЕННЯ РІВНЯ ФПН-α
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
KR100539031B1 (ko) * 1996-08-12 2005-12-27 셀진 코포레이션 면역치료제 및 이를 이용하여 사이토카인 농도를감소시키는 방법
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101502T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
WO2000055134A1 (en) * 1999-03-18 2000-09-21 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
DE19942700C1 (de) * 1999-09-07 2001-04-05 Consortium Elektrochem Ind Verfahren zur Herstellung cyclischer N-Hydroxydicarboximide
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JP4622016B2 (ja) * 1999-12-20 2011-02-02 東洋インキ製造株式会社 顔料分散剤、顔料組成物および顔料分散体
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
NZ526683A (en) * 2000-11-30 2008-03-28 Childrens Medical Center Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
DE60231989D1 (de) * 2001-08-06 2009-05-28 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
JP3578752B2 (ja) * 2001-09-28 2004-10-20 三井化学株式会社 水性インク
EP1485100B1 (en) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azinylaminoazoles as inhibitors of protein kinases
US6962940B2 (en) * 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CH696542A5 (de) 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP2505200A1 (en) * 2004-03-22 2012-10-03 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
US7244759B2 (en) * 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
NZ554068A (en) 2004-09-03 2009-07-31 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
ME01513B (me) * 2005-06-30 2014-04-20 Celgene Corp Postupak dobijanja spojeva 4-amin0-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
MX2008002765A (es) 2005-08-31 2008-04-07 Celgene Corp Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
ZA200901852B (en) 2006-09-15 2010-06-30 Celgene Corp N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
US20110021567A1 (en) 2008-03-11 2011-01-27 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
CN101531653B (zh) 2008-03-13 2014-07-09 峡江和美药业有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用

Also Published As

Publication number Publication date
JP2008544993A (ja) 2008-12-11
US20160297791A1 (en) 2016-10-13
AU2006265019B2 (en) 2011-10-13
CR9697A (es) 2008-06-26
CA2612612A1 (en) 2007-01-11
US20140256950A1 (en) 2014-09-11
BRPI0612803A2 (pt) 2012-10-02
DK2380887T3 (da) 2013-10-07
PE20070103A1 (es) 2007-02-06
HRP20130102T1 (hr) 2013-03-31
EP2380887A1 (en) 2011-10-26
IL214892A0 (en) 2011-10-31
HK1168851A1 (zh) 2013-01-11
JP2013014599A (ja) 2013-01-24
ES2402204T3 (es) 2013-04-29
PT1907373E (pt) 2013-02-18
US9822093B2 (en) 2017-11-21
AU2006265019A1 (en) 2007-01-11
JP5366544B2 (ja) 2013-12-11
CA2823088A1 (en) 2007-01-11
PL2380887T3 (pl) 2014-01-31
RS52704B (en) 2013-08-30
SI1907373T1 (sl) 2013-03-29
CA2612612C (en) 2014-03-11
US10266514B2 (en) 2019-04-23
US9394274B2 (en) 2016-07-19
ZA200800828B (en) 2009-08-26
EP1907373B1 (en) 2013-01-09
US7994327B2 (en) 2011-08-09
US20070004920A1 (en) 2007-01-04
PL1907373T3 (pl) 2013-05-31
CN102643267A (zh) 2012-08-22
KR101342241B1 (ko) 2013-12-16
IL214892A (en) 2013-11-28
KR101299321B1 (ko) 2013-08-26
CN101253163B (zh) 2012-05-02
US20110224440A1 (en) 2011-09-15
US8785644B2 (en) 2014-07-22
SI2380887T1 (sl) 2013-12-31
EP2380887B1 (en) 2013-08-07
HK1121447A1 (hr) 2009-04-24
RS53030B (en) 2014-04-30
JP5543555B2 (ja) 2014-07-09
MX2007016290A (es) 2008-03-10
ECSP088154A (es) 2008-03-26
KR20130029442A (ko) 2013-03-22
ES2430545T3 (es) 2013-11-21
NZ565309A (en) 2011-03-31
CN102643267B (zh) 2015-09-16
EP1907373A1 (en) 2008-04-09
CA2823088C (en) 2015-10-06
IL188330A0 (en) 2008-04-13
WO2007005972A1 (en) 2007-01-11
ME01513B (me) 2014-04-20
CN101253163A (zh) 2008-08-27
PE20100151A1 (es) 2010-03-05
PT2380887E (pt) 2013-09-18
US20180044318A1 (en) 2018-02-15
DK1907373T3 (da) 2013-02-04
IL188330A (en) 2013-09-30
KR20080039392A (ko) 2008-05-07

Similar Documents

Publication Publication Date Title
HRP20130966T1 (hr) Postupak dobivanja spojeva 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-3-ona
ES2587738T3 (es) Derivados de quinoxalina y quinolina como inhibidores de quinasa
EP2479172B1 (en) Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
JP2013536826A (ja) ５−フルオロ−１Ｈ−ピラゾロ［３，４−ｂ］ピリジン−３−カルボニトリルを製造する方法
CA2710447A1 (en) Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
EP2590947A1 (en) Intermediates and process for preparing a thrombin specific inhibitor
ES2340861T3 (es) Procedimientos de sintesis e intermedios para la fabricacion de rizatriptan.
ES2270144T3 (es) Procedimiento para la obtencion de compuestos de zolmitriptan.
TWI762527B (zh) 色氨酸羥化酶-１抑製劑製備方法
JP5017101B2 (ja) 不斉四置換炭素原子含有化合物の製法
NO322501B1 (no) Mellomprodukter for fremstilling av kinolonkarboksylsyre-derivater
ES2373717T3 (es) Nuevo procedimiento para preparar metanosulfonato de 4-aminometil-3-alcoxiiminopirrolidina.
AU7019700A (en) Process for production of naphthyridine-3-carboxylic acid derivatives
WO2016187028A1 (en) Heteroaryl compounds, synthesis thereof, and intermediates thereto
WO2010049500A2 (en) A process for the preparation of tadalafil.
ES2297415T3 (es) Compuesto intermedio que se utiliza para la preparacion de pioglitazona.
HUT70557A (en) N,n'-disubstituted amine derivative, pharmaceutical compositions containing them and process for producing the compounds and the compositions
US20040180898A1 (en) Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines
KR101421032B1 (ko) (2-메틸-1-(3-메틸벤질)-1Ｈ-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
Bouchnaka New Synthesis of 3-Aminohydantoins via Condensation of Hydra-zines with Isocyanates Derived from-Amino Esters
ES2418032A2 (es) Derivados de 2-(1-fenil-4,5,6,7-tetrahidro-1h-indazol-4-il)etilamina útiles como inhibidores de receptores sigma
IT202000004075A1 (it) Processo per la preparazione di panobinostat
WO2012085935A2 (en) Compounds as inhibitors of renin